Abstract We utilized a cell-level approach to examine glycolytic pathways in the DLPFC of subjects with schizophrenia (n = 16) and control (n = 16) and found decreased mRNA expression of glycolytic enzymes in pyramidal neurons, but not astrocytes. To replicate these novel bioenergetic findings, we probed independent datasets for bioenergetic targets and found similar abnormalities. Next, we used a novel strategy to build a schizophrenia bioenergetic profile by a tailored application of the Library of Integrated Network-Based Cellular Signatures data portal (iLINCS) and investigated connected cellular pathways, kinases, and transcription factors using Enrichr. Finally, with the goal of identifying drugs capable of Breversing^the bioenergetic schizophrenia signature, we performed a connectivity analysis with iLINCS and identified peroxisome proliferator-activated receptor (PPAR) agonists as promising therapeutic targets. We administered a PPAR agonist to the GluN1 knockdown model of schizophrenia and found it improved long-term memory. Taken together, our findings suggest that tailored bioinformatics approaches, coupled with the LINCS library of transcriptional signatures of chemical and genetic perturbagens, may be employed to identify novel treatment strategies for schizophrenia and related diseases.
Introduction
Schizophrenia is a devastating illness that affects over 2 million people in the USA and displays a wide range of symptoms [1] [2] [3] [4] [5] [6] . Cognitive impairment is a hallmark feature of the illness, and antipsychotics have poor efficacy in treating cognitive decline [7, 8] . The dorsolateral prefrontal cortex (DLPFC) is a brain region heavily implicated in the pathophysiology of Courtney R. Sullivan and Catharine A. Mielnik are co-first authors.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12035-018-1390-4) contains supplementary material, which is available to authorized users. schizophrenia, possibly contributing to defects in working memory [9] . A variety of abnormalities have been reported in the DLPFC of schizophrenia patients, including changes in gene expression, cell density, receptor binding, and cerebral blood flow [10] [11] [12] . There is also accumulating evidence of bioenergetic dysfunction in chronic schizophrenia, which has recently been reviewed and highlights a number of abnormalities associated with glucose metabolism, the lactate shuttle, and bioenergetic coupling [13] . There is also evidence for genetic linkage between enzymes that control glycolysis in schizophrenia including 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) and hexokinase 3 (HK3), suggesting that genetic risk for this illness includes bioenergetic substrates [14] . Interestingly, studies using cell-level techniques have demonstrated complex bioenergetic changes, including decreases in mitochondrial oxidative energy metabolism genes in dentate granule neurons (n = 22 subjects) and in layer 3 and 5 pyramidal neurons from the DLPFC (n = 36 and n = 19 subjects) in schizophrenia [15] [16] [17] . Decreases in metabolic transcripts included lactate dehydrogenase A (LDHA), nicotinamide adenine dinucleotide dehydrogenases (NADH), and adenosine triphosphate (ATP) synthases. We have also recently demonstrated decreases in glycolytic enzymes (HK1, and phosphofructokinase muscle type, PFKM) and glucose transporters (GLUT1 and GLUT3) in pyramidal neurons, but not astrocytes, in the DLPFC of schizophrenia subjects (n = 16) [18] . While examining the expression of individual targets is important, employing a signature-based bioinformatics approach may help elucidate the pathophysiology of large biological networks.
Complex illnesses such as schizophrenia are rarely a consequence of an abnormality in the expression of a single gene, but rather a combination of abnormalities in complex cellular networks. This study employs a novel strategy to derive and analyze molecular signatures of schizophrenia by using the Library of Integrated Network-based Cellular Signatures (LINCS). LINCS is an online reference library of cell-based perturbation-response Bsignatures^of both chemical (small drug-like molecule) and genetic (gene knockdown) perturbations, employing a wide range of assay technologies cataloging diverse cellular responses at the transcriptome, proteome, and other levels [19] . The reference library used here includes data on the expression of 978 landmark genes (L1000 genes) following the genetic knockdown of genes in various cell lines (with the changes in the L1000 genes from a single genetic perturbation called Bknockdown signatures^). The rationale is that the selected landmark genes would capture most of the information contained within the transcriptome, allowing researchers to examine disease associated changes at the network level [20] . Over 100 cell types have been used to build the LINCS database, and model systems include proliferating immortal cell lines, primary cultures, and induced pluripotent stem cells (iPSCs) [19] .
Our bioinformatic strategy relies on the iLINCS web portal for querying and complex analyses of LINCS data (http:// ilincs.org) to systematically explore the biological underpinning of schizophrenia associated gene expression changes and identify candidate therapeutic strategies from network-based molecular changes (Fig. 1) . We began by modeling a schizophrenia bioenergetic profile in iLINCS based on two new cell-level findings from this study (PFK liver type, PFKL, and glucose-6-phosphate isomerase, GPI), previously identified gene expression changes from cell-level studies (HK1, PFKM, LDHA) [15, 18] , and a published genetic linkage study (PFKFB2) [14] . The genes comprising our schizophrenia bioenergetic profile are involved in both glycolysis and the lactate shuttle, and are referred to as Bseed genes (  Table 1 ). iLINCS may be queried for each seed gene to determine if a knockdown signature has been catalogued in the database. By clustering the seed gene knockdown signatures in iLINCS, we are able to analyze the connectivity of the knockdown signatures (and thus establish a schizophrenia bioenergetic profile), identifying groups of L1000 genes that change concordantly following genetic perturbation. Furthermore, we can perform Enrichr analyses on these genes to gain perspective on bioenergetic pathology, describe potential multisystem pathological mechanisms, and inform pharmacological studies.
Next, we aimed to identify therapeutic compounds with the potential to Breverse^glycolytic deficits as well as the associated changes in the L1000 genes. In order to select a potential drug intervention for preclinical testing, we relied on the Bconnectivity^analysis to reveal positively (concordant) and negatively correlated (discordant) chemical (small molecule) and genetic perturbations. We developed a discovery-based workflow to generate a list of small molecule perturbagens with L1000 transcript changes in the opposite direction of our knockdown signatures (based on concordance values from iLINCS, i.e., generating an Binverse/discordant signature^) (Fig. 1) . iLINCS provides over 40,000 transcriptomic profiles (signatures) from different cell lines treated with chemical perturbagens such as Food and Drug Administration (FDA)-approved drugs, chemical probes, and screening library compounds including those with clinical utility and known mechanisms of action [19] . FDA-approved drugs generated from this Bknockdown signature connectivity^analysis could serve as candidates for therapeutic treatment in a preclinical model of schizophrenia. Peroxisome proliferator-activated receptor (PPAR) agonists had multiple hits in our analysis and similar drugs in this class are currently FDA approved for use in humans [21] .
One of the leading hypotheses of the etiology of schizophrenia is glutamatergic hypofunction [22] [23] [24] . N-methyl-Daspartate (NMDA) subtype glutamate receptor dysfunction is strongly implicated in the pathophysiology of schizophrenia, particularly in human pharmacological studies [25] [26] [27] [28] . Fig. 1 Overview of bioinformatic workflow. We began by performing literature searches and further characterizing cell-level postmortem bioenergetic abnormalities in schizophrenia. Based on these findings, we established a bioenergetic seed profile containing six glycolytic genes implicated in schizophrenia (Bseed genes^). To replicate our bioenergetic findings in schizophrenia, we probed a publicly available microarray database (Stanley Medical Research Institute Online Genomics Database), microarray data from the DLPFC of control and schizophrenia subjects (Mount Sinai School of Medicine, Bronx VAMC mRNA dataset), and RNAseq data from frontal cortical neurons of a patient with schizophrenia and DISC1 mutation [76] . Next, we used iLINCS (http://ilincs.org) to retrieve knockdown signatures for each seed gene individually. With the goal of identifying panels of correlated transcriptomic changes in our seed gene KD signatures, we used iLINCS to perform unsupervised clustering of the top 50 differentially expressed L1000 genes from our six seed gene KD signatures. The panels of clustered differentially expressed L1000 genes were carried forward to Enrichr analyses. We also performed iLINCS connectivity analyses and identified peroxisome proliferator-activated receptor (PPAR) agonists as promising therapeutic targets with the potential to Breverse^glycolytic deficits as well as the associated changes in the L1000 genes. Finally, we administered the PPAR agonist pioglitazone to the GluN1 knockdown model of schizophrenia and examined endophenotypes of schizophrenia. Phosphofructokinase liver type (PFKL); PFK muscle type (PFKM); glucose-6-phosphate isomerase (GPI); 6-phosphofructo-2-kinase (PFKFB2); lactate dehydrogenase A (LDHA); hexokinase 1 (HK1); fold change (FC); inducible pluripotent stem cells (IPSC); knockdown (KD) Converging evidence suggests that NMDA receptor hypofunction may actually reflect a dysregulation at the receptor level, including mutations in NMDA receptor subunits [29] . Several studies have found associations between the gene that encodes the GluN1 subunit of the NMDA receptor (Grin1) and schizophrenia [30] [31] [32] [33] [34] [35] [36] [37] [38] . The GluN1 knockdown mouse model has a~90% global reduction of normal functioning NMDA receptors, achieved by targeted insertion of 2 kb of foreign DNA into intron 19 of the Grin1 gene [39] . Additionally, mice with mutations in the Grin1 gene have well-characterized behavioral endophenotypes of schizophrenia; this includes impairments in executive function and working memory, increased stereotypic behavior, decreased anxiety-like behavior, decreased sensorimotor gating, and abnormal social interaction [40] . Several of these behaviors are attenuated by typical and atypical antipsychotics at doses similar to those used in pharmacological models of schizophrenia (MK-801 or phencyclidine models), including hyperactivity, stereotypy, and sociability deficits [39, 41] . Therefore, the GluN1 knockdown mouse model is a viable and useful tool for studying the interface of NMDA receptor hypofunction, bioenergetics, and schizophrenia symptomology.
There is evidence of abnormal bioenergetic pathways in GluN1 knockdown animals and other models of impaired synapses. For example, there is strong evidence linking lactate shuttle defects to NMDA receptor dysfunction in MK-801-treated rats and in GluN1 knockdown mice [42] [43] [44] . Dysregulation of the energetic flow of lactate inhibits longterm potentiation [45, 46] , and may contribute to cognitive deficits in GluN1 knockdown mice. Additionally, when lactate flow from astrocytes to neurons is stimulated, or when lactate is introduced to the extracellular space, it enhances working memory and memory formation in rats [45] [46] [47] . Thus, drug-induced stimulation of lactate production coupled with behavioral studies in GluN1 knockdown mice could help elucidate the role of bioenergetic abnormalities in cognitive dysfunction in schizophrenia.
Pioglitazone is a member of the thiolazinedione (TZD) drug family (that appeared in our knockdown signature connectivity analysis) that is approved to treat type 2 diabetes and hyperglycemia [48] . Pioglitazone is a synthetic ligand for PPARγ, a nuclear receptor that is responsible for the regulation of several bioenergetic functions such as lipid homeostasis, adipocyte differentiation, and insulin sensitivity [48, 49] . Interestingly, PPARγ agonists have the ability to reduce oxidative stress (via mediating nitric oxide production) as well as modifying mitochondrial metabolism by interacting with proteins associated with mitochondrial function (mitoNEET proteins) [49] [50] [51] [52] [53] . Activation of PPARγ via pioglitazone can also alter the transcription and expression of GLUT1, leading to changes in glucose uptake through PPARγ and other mechanisms [48, 54] . Thus, we hypothesize that treatment with pioglitazone will help restore cognitive endophenotypes associated with schizophrenia in the GluN1 knockdown model via stimulation of metabolic pathways.
In our final experiment, we treated animals with pioglitazone and measured various behavioral outputs that are endophenotypes for schizophrenia [55, 56] . First, we assessed locomotor activity, stereotypic behaviors, and mania-like behavior. Next, we assessed executive function and cognitive flexibility using the puzzle box test. This test requires the mouse to display problem-solving behavior as well as shortand long-term explicit memory to reach a goal area. To assess pioglitazone's effect on sociability, we used an age-and sexmatched mouse as a social stimulus [57] . Finally, we assessed sensorimotor gating using the pre-pulse inhibition (PPI) of acoustic startle paradigm [58] . Taken together, these studies provide a translational bioinformatics approach to identify novel treatment strategies through the use of the LINCS library of signatures and connectivity analysis, coupled with the analyses of primary data and published work.
Results

Laser Capture Microdissection-Quantitative Polymerase Chain Reaction Studies
We used laser capture microdissection coupled with quantitative polymerase chain reaction (LCM-qPCR) to assess mRNA expression of our metabolic targets in enriched populations of astrocytes and pyramidal neurons in schizophrenia and control subjects (Table S1 and S2). We have previously shown our LCM samples are enriched for specific cell-subtypes using neurochemical markers [11, 18, 59, 60] . No significant associations were found between pH, postmortem interval (PMI), RNA integrity number (RIN), or age and any of our dependent measures. In a sample enriched for pyramidal neurons, we found decreases in PFKL (27%, p = 0.010) and GPI (26%, p = 0.015) mRNA expression (Fig. 2 , p < 0.05). We did not detect any significant changes in mRNA expression in samples enriched for astrocytes (Fig. S1 ). To assess the use of antipsychotic medication in our patient population, we reanalyzed our significant cell-level targets with and without antipsychotic naïve subjects. All findings remained significant without these subjects (PFKL p = 0.037, GPI p = 0.034) (Fig.  S2 , panels A and B). We also assessed the effects of antipsychotics on PFKL and GPI in multiple brain regions in the Stanley Medical Research Institute (SMRI) genomics database and detected an effect on GPI (p = 0.006, fold change = 1.09), but not PFKL (p = 0.09, fold change = 1.06). However, this effect was in the opposite direction of our findings, suggesting the decreased expression in pyramidal neurons in schizophrenia is not due to a medication effect. Additionally, we assessed the effects of ethanol use, smoking, and laterality on our dependent measures in schizophrenia subjects via secondary analyses of schizophrenia subjects on and off ethanol, smokers/nonsmokers, and left/right brain and did not detect any effects (Fig. S2 , panels C-H).
Generation of Schizophrenia Bioenergetic Profile (Seed Genes)
We built a schizophrenia bioenergetic gene profile of six glycolytic genes based on data from our cell-level postmortem findings (HK1, PFKM, PFKL, GPI) and the literature (LDHA, PFKFB2). These Bseed genes^were used in subsequent Blookup^replication studies, iLINCS clustering analyses (followed by Enrichr analysis), and iLINCS connectivity analyses (drug discovery analysis using Binverse/discordantŝ ignatures). Figure 1 summarizes the bioinformatic work flow for both clustering and connectivity analyses.
BLookup^Replication Studies for Seed Genes
To replicate our bioenergetic findings, we performed in silico validation studies (Blookup^studies) using three independent datasets (SMRI genomic database, Mount Sinai School of Medicine (MSSM) database, and a frontal cortical neuron RNAseq dataset generated from iPSCs of a patient with schizophrenia and disrupted in schizophrenia 1 (DISC1) mutation [61] ). Table 2 summarizes findings from this study and previous studies in our laboratory, as well as the mRNA expression of our selected seed genes (LDHA, HK1, PFKM, PFKL, GPI, PFKFB2) in each dataset.
LDHA is significantly downregulated in both the SMRI (− 1.11 FC, p = 0.022) and frontal cortical neuron RNAseq (− 2.50 FC) dataset, while PFKFB2 was downregulated in both the MSSM microarray (− 1.31 FC) and frontal cortical neuron RNAseq (− 1.14 FC) dataset. PFKL was also significantly downregulated in the frontal cortical neuron RNAseq dataset (− 1.12 FC). Many seed genes were unchanged in the SMRI and MSSM datasets. However, the SMRI database is an aggregate of five brain regions and the MSSM dataset utilized blended samples from the whole DLPFC, while our findings are from cell-level studies. This is supported by 3/6 seed genes being above our fold change threshold in the cell-level frontal cortical neuron RNAseq dataset.
Generation of Seed Gene Knockdown Signatures
We used iLINCS (http://ilincs.org) to retrieve knockdown signatures for each seed gene individually. Each seed gene knockdown signature (GPI knockdown signature, HK1 knockdown signature, PFKM knockdown signature, PFKL knockdown signature, LDHA knockdown signature, PFKFB2 knockdown signature) is comprised of the transcriptional changes of 978 landmark genes (L1000 genes) when that seed gene is knocked down (Fig. S3 ). Only signatures designated to be reproducible and self-connected (Bgold^) by the Broad Institute are available. When multiple shRNAs are available for gene knockdown experiments, consensus gene knockdown signatures, as defined by iLINCS, are used. To minimize variability, we compared signatures for seed genes using one consistent cell line (vertebral-cancer of the prostate, VCAP).
iLINCS Clustering Analyses
For unsupervised clustering analyses, we used iLINCS to cluster the union of the top 50 differentially expressed L1000 genes from each of the six seed gene knockdown signatures using Pearson correlation coefficients (Figs. 3 and 4) . Due to gene overlap between the top 50 differentially expressed L1000 genes in seed gene knockdown signatures, this resulted in the clustering of expression data for 260 L1000 genes. We next used the dendrogram function in iLINCS to select panels of genes with increased expression across clustered seed gene knockdown signatures (Bpanels of clustered upregulated genes^) and with decreased expression across clustered seed gene knockdown signatures (Bpanels of clustered downregulated genes^). These clustered gene panels (Table S3) were carried forward to two separate Enrichr analyses.
Enrichr Analyses of Panels of Clustered Upregulated Genes
We performed Enrichr analyses on panels of clustered upregulated genes from our iLINCS clustering analysis. Top cell signaling pathways included forkhead box O (FOXO), mitogenactivated protein kinase (MAPK), and Wnt signaling pathways (Fig. S4) . These pathways often interact and all have important roles in cell metabolism, inflammation, cellular proliferation, Fig. 2 mRNA expression in pyramidal neurons. Relative expression levels of glucose-6-phosphate isomerase (GPI) and phosphofructokinase liver (PFKL) transcripts in enriched pyramidal neuron populations from schizophrenia (SCZ, n = 16) and control (CTL, n = 16) subjects (A). Data from pyramidal neuron enriched samples were normalized to the geometric mean of three housekeeping genes (B2M, PPIA, ACTB). Data are expressed as percent control ± SEM. *p < 0.05 oxidative stress prevention, and apoptosis [62] [63] [64] [65] . Analysis of gene ontology (GO) cellular components for our panels of clustered upregulated genes included several microtubule and cytoskeletal components (Fig. S5) , while the top hits for GO molecular function included protein kinase C (PKC) and MAPK binding (Fig. S6) . Our protein-protein interactions analysis (Fig. S7 ) yielded multiple hits for protein kinases such as ribosomal Protein S6 Kinase A3 (RPS6KA3), MAPK14, glycogen synthase kinase 3 beta (GSK3B), and cyclin-dependent kinase 1 (CDK1). We also found hits for proteins involved in protein degradation and protein ubiquitination (cullin 1, CUL1, and Sphase kinase associated protein 1, SKP1), chromatin remodeling (proliferating cell nuclear antigen, PCNA, and histone deacetylase 1, HDAC1), and an estrogen receptor (ESR1).
We next probed for kinases that when knocked down in various cell lines have upregulated genes similar to the panels of clustered upregulated genes from our iLINCS clustering analysis. Top hits included several serine/threonine-protein kinases (serine/threonine-protein kinase akt 1 (AKT1), mitogenactivated protein kinase kinase 2 (MAP2K2), protein tyrosine kinase 2 (PTK2), ataxia telangiectasia and Rad3-related protein (ATR)) as well as G protein coupled receptors (GPCRs) involved in energy homeostasis (neuromedin U receptor 2 (NMUR2), free fatty acid receptor 1 (FFAR1)) (Fig. S8) . We next probed for transcription factors that had occupancy sites for our panels of clustered upregulated genes. We found several transcription factors that play important roles in developmental processes, such as Wilms tumor 1 (WT1), tripartite motifcontaining 28 (TRIM28), nuclear factor I B (NFIB), nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1), and transcription factor 3 (TCF3) (Fig. S9) . Finally, our database of genotypes and phenotypes (dbGaP) analysis implicates diabetes as the most relevant phenotype (Fig. S10) . A summary of these findings can be found in Table 3 .
Enrichr Analyses of Panels of Clustered Downregulated Genes
We performed Enrichr analyses on our panels of clustered downregulated genes from our iLINCS clustering analysis. Top cell signaling pathways include pathways relevant to immune/inflammatory responses and cell cycle regulation (Fig. S11) . The top 5 hits in our GO cellular components analysis for our panels of clustered downregulated genes implicated mitochondrial function (Fig. S12) , while the top hits for GO molecular function included several RNA polymerase promotors/activators (Fig. S13) . Our protein-protein interactions analysis (Fig. S14 ) yielded multiple hits for chromatin remodeling proteins (PCNA, HDAC1, HDAC2, CREB binding protein (CREBBP)). We also found hits for proteins involved in immunity/cell cycle regulation (nuclear factorkappa-B 2 (NFKB2), casein kinase II subunit alpha 1 (CSNK2A1), MYC proto-oncogene (MYC)) and ubiquitination (BReast CAncer gene 1, BRCA1).
We next probed for kinases that when knocked down in various cell lines have downregulated genes similar to our panels of clustered downregulated genes from our iLINCS clustering analysis. Top hits included several kinases involved in fatty acid metabolism and energy homeostasis (retinoid X receptor alpha (RXRA), PPARG, PX domain containing serine/threonine kinase like protein (PXK)), cellular growth (receptor-like tyrosine kinase (RYK), WEE1 kinase (WEE1), Abelson murine leukemia 2 (ABL2)), GPCRs (G protein coupled receptor 37 (GPR37), latrophilin 1 (LPHN1)), and a glucocorticoid receptor (nuclear receptor subfamily 3 group C member 1, NR3C1) (Fig. S15) .
We next probed for transcription factors that had occupancy sites for our panels of clustered downregulated genes. We found several transcription factors that play important roles in Summary of region and cell-level seed gene findings from this human postmortem study and online databases. Mount Sinai School of Medicine (MSSM) database compares microarray data from the dorsolateral prefrontal cortex (DLPFC) in schizophrenia (n = 16) and control (n = 15) subjects. Stanley Medical Research Institute (SMRI) Genomics database compares microarray and consortium data from schizophrenia (n = 50) and control (n = 50) subjects from five postmortem brain regions (BA6, BA8/9, BA10, BA46, cerebellum cell proliferation (MYCN, MYC, E2F transcription factor 1 (E2F1), E2F4, forkhead box M1 (FOXM1)), development (NUCKS1, POU class 5 homeobox 1 (POU5F1)), and erythroid function (erythroid Kruppel like factor 1, EKLF) ( Fig.  S16 ). Finally, our dbGaP analysis implicates carcinoma, memory, and Grave's disease as the most relevant phenotypes (Fig.  S17) . A summary of these findings can be found in Table 3 .
iLINCS Connectivity Analyses (Drug Discovery)
Using the connected signatures function in iLINCS, we identified chemical perturbagens that produce L1000 signatures that are highly discordant (anti-correlated) with our seed gene knockdown signatures. We generated concordance values (defined in terms of the Pearson correlation coefficients for the gene expression vectors representing the signatures) for every perturbagen in the database, comparing each seed gene knockdown signature to each perturbagen signature separately. The top 20 discordant perturbagen for each seed gene knockdown signature are shown in Table S4 (GPI and PFKM had less than 20 discordant chemical perturbagens, PFKFB2 had none). HK1 and PFKL generated the top 20 perturbagens with the highest discordance (average of − 0.4). LDHA, GPI, and PFKM had perturbagen signatures with an average discordance of − 0.2 to − 0.3. PFKFB2 had no significantly discordant perturbagen signatures. Next, we combined all discordant perturbagens from Table S4 and reported the top 20 overall discordant perturbagen signatures across all seed gene knockdown signatures (Table S5 ). After removing duplicate hits, 12 unique perturbagens remained (Table 4) . Hits included PPARγ agonists (troglitazone and genistein), valproic acid (a voltagegated sodium channel blocker and HDAC inhibitor), typical antipsychotic drugs (trifluoperazine, thioridazine, and fluphenazine), and two phosphoinositide 3-kinase (PI3K) inhibitors (Wortmannin and LY-294002). We selected the FDAapproved PPARγ agonist pioglitazone for preclinical trials due to its ability to regulate glycolytic pathways that are abnormal in schizophrenia, as well as evidence that pioglitazone treatment improves negative symptoms in patients [54, 66, 67] . One study reported no changes in overall neuropsychological status following pioglitazone treatment in patients; however, no cognitive tasks using domain-specific subtests have been studied [67] .
Confirming Bioenergetic Defects in GluN1 Knockdown Mice
To examine the proteome in GluN1 knockdown mice and wild-type (WT) mice (three male mice/group), we used a mouse anti-postsynaptic density 95 (PSD95) antibody to capture PSD95 protein complexes from samples. The affinity purified samples were enriched for PSD95 when compared to the supernatant and total homogenate (Fig. 5a ). Following mass spectrometry on affinity purified samples, we analyzed the top 20 increased proteins in GluN1 knockdown mice relative to WT mice with Ingenuity Pathway Analysis (IPA). The top 5 implicated pathways in the GluN1 knockdown mice were gluconeogenesis, glucose metabolism, pyruvate and citric acid metabolism, metabolism of carbohydrates, and glycogen storage disease (Fig. 5b) .
Finally, we examined mRNA expression of metabolic transporters (MCT1, MCT2, MCT4, GLUT1, GLUT3) using RT-qPCR in a different cohort of GluN1 knockdown and WT mice (n = 5 per group). We found significant decreases in GLUT1 (47%, p = 0.018) and GLUT3 (34%, p = 0.013) in GluN1 knockdown mice compared to WT controls ( Fig. 5c ), replicating results from postmortem schizophrenia and confirming that a strategy to increase glucose uptake capacity might be a successful intervention for this disorder.
GluN1 Knockdown Pioglitazone Studies
For pioglitazone studies (in a different cohort of mice, Table S6 ), we assessed caloric intake and body weight to ensure pioglitazone treatment did not have adverse effects. Pioglitazone did not affect the intake of chow or the body weight of the animals (p = 0.5096) (Fig. S18 ).
In the puzzle box assay, we found that 1 week of pioglitazone treatment decreased (improved) time to perform task in (Fig. 7, panels b-d) . GluN1 knockdown mice, when compared to WT littermates, displayed an increase in hyperlocomotion, as quantified by an increase in total distance traveled measured in centimeters, which was accompanied by an increase in overall stereotypic movements and rearing. We did not detect changes in hyperactivity, stereotype, or vertical activity in GluN1 knockdown mice following pioglitazone treatment (Fig. 7, panels b-d) .
In the elevated plus maze (EPM), we detected an effect of genotype (p < 0.0001). GluN1 knockdown animals spent significantly more time in the open arms than did WT mice, regardless of pioglitazone/vehicle treatment ( 6 Puzzle box assay. Latency (s) to complete trials in puzzle box expressed as a time course (significance not denoted) (a). Latency (s) to goal zone in puzzle box in WTveh (n = 12), WTpio (n = 10), GluN1veh (n = 9), and GluN1pio (n = 12) mice (b). Trial 1 of the puzzle box assay demonstrating a decrease in latency to goal zone in GluN1pio mice when compared to GluN1veh (c). Trial 4 of the puzzle box assay demonstrating a decrease in latency to goal zone in GluN1pio mice when compared to GluN1veh (d). Only drug significance (not genotype) is denoted. Data are shown as mean ± SEM. p < 0.05 and is observed in mouse models of mania-like behavior. We did not detect any significant differences in genotype or drug treatment in social affiliated behavior (Fig. S20) .
Finally, in measures of sensorimotor gating (PPI), we detected an effect of genotype on PPI at 4 dB (F (1, 23) = 20.06, p = 0.0002), 8 dB (F (1, 23) = 15.63, p = 0.0006), and 16 dB (F (1, 23) = 9.177, p = 0.0060). GluN1 knockdown mice had generally lower PPI than did WT controls at all decibels. Additionally, at 4 dB, pioglitazone-treated GluN1 knockdown (GluN1pio) mice had a lower PPI than any other group (Fig. 8 , panel a), suggesting pioglitazone interacts in a negative way with the knockdown pathophysiology (drug by genotype interaction, F (1, 23) = 6.579, p = 0.0173). We did not detect any differences in the acoustic startle response between any groups, although GluN1 knockdown animals tended to have higher startle responses (Fig. 8, panel b) .
Discussion
Big biomedical data resources, such as LINCS, open new avenues for innovative analyses of primary data generated in conjunction with focused, hypothesis-driven research being undertaken in individual research labs. Interdisciplinary studies that combine such resources and research expertise in neuroscience, bioinformatics, and data science can greatly enhance our ability to generate novel hypotheses and offer key insights into the mechanisms of human disease. The goal of this study was four parts: first, to further characterize changes in glycolytic enzyme expression at the cellular level in schizophrenia and to explore these findings in available in silico databases; second, to analyze the connectivity of bioenergetic pathology in schizophrenia by generating a schizophrenia bioenergetic profile in iLINCS and performing pathway analyses on panels of clustered genes that are highly differentially expressed across knockdown signatures; third, to generate a list of promising drug interventions with the goal of future preclinical testing; and fourth, to examine endophenotypes of schizophrenia following treatment with an FDA-approved drug identified by our bioinformatic analyses in an animal model.
Cell-Level Postmortem Studies
Our findings of decreased PFKL and GPI mRNA in pyramidal neurons build upon previous reports of abnormalities in glycolytic enzymes, as well as glucose/lactate transporters, in the DLPFC in schizophrenia [18] . PFKL codes for the liver (L) subunit of the PFK enzyme, which catalyzes the phosphorylation of fructose 6-phosphate to fructose 1,6-bisphosphate in the third, irreversible and rate-limiting step of glycolysis [68] . There are several tetrameric isoforms of the PFK enzyme, each comprised of different combinations of L, muscle (M), or platelet (P) subunits. The PFK-5 protein is entirely comprised of L subunits, while the PFK-1 protein is entirely comprised of M subunits. Other erythrocyte PFK enzymes are composed of heterogeneous subunits, and all PFK enzymes are found in the brain [68] . Under conditions of high glycolytic flux, cells can divert glucose to the pentose phosphate pathway; however, the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate by PFK commits glucose to the glycolytic pathway. As a gatekeeper in the metabolic degradation of glucose, PFK is highly regulated, both by downstream metabolites and its strong allosteric activator fructose 2,6-bisphosphate (F2,6BP), which is produced by PFKFB when glycolysis is upregulated (Warburg effect) [69] . Notably, knockdown of PFKL impairs glycolysis and promotes metabolism via the pentose phosphate pathway [70] . Decreases in PFKL or PFKM expression in schizophrenia could affect normal enzyme activity, resulting in either decreased glycolytic breakdown of glucose or an inability to upregulate glycolysis when energy demand is high. Interestingly, the human PFKL gene is located on chromosome 21 and abnormal expression of PFKL is associated with the cognitive illness Down's syndrome [71] . Additionally, we previously reported decreased PFK activity in the DLPFC of schizophrenia subjects [18] .
We also found a decrease in the mRNA expression of GPI in an enriched population of pyramidal neurons in schizophrenia. GPI is a dimeric cytoplasmic enzyme that catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate in the second step in the glycolytic pathway. When expressed extracellularly, the GPI protein functions as a neurotrophic factor that promotes neuronal survival [72] . One study found an increase in glucose-6-phosphate levels, as well as several other metabolites in the glycolytic pathway, in peripheral blood mononuclear cells of schizophrenia patients, suggesting improper functioning of glycolytic enzymes [73] . Other data suggest that GPI deficiency results in an accumulation of glucose-6-phosphate and over activation of the mammalian target of rapamycin (mTOR) pathway [74] . A decrease in GPI expression in pyramidal neurons could contribute to dysregulation of both glycolysis and mTOR signaling. A disruption in mTOR signaling could affect protein synthesis and lead to aberrant neuronal growth and synapse connectivity. Supporting this hypothesis, the mTOR pathway has been previously implicated in schizophrenia [75] .
Schizophrenia Bioenergetic Profile (Seed Genes)
Based on strong cell-level evidence from this study and prior work, as well as decreases in glycolytic enzyme activity, we generated a schizophrenia bioenergetic profile consisting of six functionally related genes [14, 15, 18] . These six genes (Bseed genes^) are strong glycolysis regulators and critical steps in the glycolytic pathway. The six seed genes in our profile were used for lookup replication studies, iLINCS clustering, and iLINCS connectivity (drug discovery) analyses.
BLookup^Replication Analyses
We sought to replicate our metabolic LCM findings, as well as explore the mRNA expression of seed genes through in silico Blookup^analyses [18] . In our LCM studies, we found decreases in HK1, PFKM, PFKL, and GPI in pyramidal neurons in the DLPFC in schizophrenia (Fig. 2, Table 2 ) [18] . We probed a second cell-level dataset (frontal cortical neurons differentiated from iPSCs of schizophrenia subjects with the DISC mutation [76] ) and found that 3/6 of our seed genes were abnormally expressed (LDHA, PFKL, and PFKFB2) ( Table 2 ) [76] . LDHA, which was previously found to be downregulated in dentate granule neurons in schizophrenia, was also significantly downregulated in the SMRI genomics database [15] . We also found that PFKFB2, which is genetically linked to schizophrenia, is downregulated in schizophrenia in the MSSM DLPFC microarray data [14] . The SMRI and the MSSM databases contain region-level findings in multiple brain regions, while iPSCs and LCM techniques provide cell-subtype specific resolution. Further, prior work in our laboratory found a decrease in PFK and HK enzyme activity levels in the DLPFC in schizophrenia [18] . These findings suggest our seed genes are dysregulated at the cell, region, transcript, and functional level in schizophrenia, as well as by genetic association.
Generation of Seed Gene Knockdown Signatures
We used iLINCS (http://ilincs.org) to retrieve knockdown signatures for each seed gene individually. Each seed gene knockdown signature (GPI knockdown signature, HK1 knockdown signature, PFKM knockdown signature, PFKL knockdown signature, LDHA knockdown signature, PFKFB2 knockdown signature) is comprised of the transcriptional changes of 978 landmark genes (L1000 genes) when that seed gene is knocked down (Fig. S3) .
Panels of Clustered Upregulated and Downregulated Gene Identification
After clustering the knockdown signatures of our six seed genes in iLINCS, we (separately) selected panels of clustered upregulated and downregulated genes using the interactive dendrogram function. This resulted in 67 upregulated and 69 downregulated genes carried forward to Enrichr analyses.
Enrichr Analysis of Upregulated Genes from iLINCS Clustering
We began by using Enrichr to identify pathways associated with our panels of clustered upregulated genes from our iLINCS clustering analysis (Fig. 3, Figs. S4-S10 ). Using KEGG, we generated top cell signaling pathways which returned hits such as FOXO, Wnt, and MAPK signaling. These signaling pathways implicate glucose utilization, energy homeostasis, mitochondrial function, and cell growth. Our top protein-protein interaction hits (RPS6KA3, MAPK14, GSK3B, CDK1, etc.) suggest a role for pathways involved in energy metabolism and cell proliferation. Next, we probed for kinases that increased the expression of genes that were in our panels of clustered upregulated genes when knocked down in specific cell lines. We found several serine/ threonine-protein kinases including AKT1, PTK2, MAP2K2, and ATR. AKT1 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2, and AKT3) thought to regulate metabolism and promote cellular proliferation [77] . We also had significant hits for GPCR proteins NMUR2 and FFAR1. NMUR2 encodes a G protein coupled receptor protein widely expressed in the central nervous system (CNS) that binds the neuropeptide neuromedin U in order to regulate energy homeostasis [78, 79] . These results suggest that kinases involved in glucose metabolism and cell cycle regulation are relevant to our panels of clustered upregulated genes. Finally, we performed pathway analyses to identify transcription factors with occupancy sites for our panels of clustered upregulated genes, several of which played key roles in neurodevelopment (WT1, NFIB, TCF3, TRIM28, etc.). Our transcription factor analysis also generated hits for estrogen receptors (ESR1, ESR2), tumor suppressors/activators (ETS Transcription Factor, ELK3), and transcription factors involved in immune responses and macrophage function (CCAAT/enhancer-binding protein beta, CEBPB) [80, 81] . Enrichr analyses are summarized in Table 3 and a full discussion of panels of clustered upregulated genes can be found in the online resources.
Enrichr Analysis of Downregulated Genes from iLINCS Clustering
We used Enrichr to identify pathways associated with our panels of clustered downregulated genes from our iLINCS clustering analysis (Fig. 4, Figs. S11-S17 ). Using KEGG, we generated top cell signaling pathways which returned hits such as human T-lymphotropic virus (HTLV) infection, hepatitis B, p53 signaling, and cell cycle pathways (Fig. S11) . This implicates inflammation, impaired immunity, and cell proliferation. The top 5 hits in our GO cellular components analysis for panels of clustered downregulated genes implicate mitochondria and oxidative phosphorylation (Fig. S12) . The top hits of our protein-protein interaction analysis (Fig. S14) for panels of clustered downregulated genes included HDAC1 and HDAC2, a ubiquitously expressed protein that removes acetyl groups from lysine residues on core histones [82] . Other top hits in our protein-protein interaction analysis include PCNA and BRCA1, which also bind HDAC1 and are involved in epigenetics, DNA replication, and DNA repair [83] . Interestingly, HDAC1 is increased in the prefrontal cortex and hippocampus in schizophrenia and overexpression of HDAC1 leads to impairments in working memory [84] [85] [86] . There are accumulating instances of schizophrenia patients with mutations in genes encoding chromatin regulators (such as histone modifying enzymes and transcription factors) [87] . Other hits included transcription factors involved in inflammation and the balance of activation and suppression of cellular proliferation processes (Table 3) . Next, we probed for kinases that when knocked down in specific cell lines decreased the expression of genes that were in our panels of clustered downregulated genes (Fig. S15) . We found multiple kinases with important roles in glucose homeostasis and energy metabolism. The nuclear receptor PPARγ forms a heterodimer with the RXR, two of our top hits, increasing the transcription of various genes that stimulate glucose uptake and carbohydrate metabolism [88] . PPARγ ligands such as TZDs increase glucose utilization, treat hyperglycemia, and represent therapeutic possibilities in diseases with deficient glycolytic systems [89] . We also found kinases that are involved in axonal growth during CNS development (RYK), cell growth and cycle progression (WEE1, ABL2), and cytoskeletal remodeling (ABL2). Finally, we performed pathway analyses to identify transcription factors with occupancy sites for our panels of clustered downregulated genes, several of which played key roles in cellular proliferation/development and were similar to hits from previous analyses (MYC, MYCN, NUCKS1, FOXM1) (Fig. S16) . Enrichr analyses are summarized in Table 3 and a full discussion of panels of clustered downregulated genes can be found in the online resources.
In summary, we extrapolated on the abnormalities of glycolytic enzymes using Enrichr pathway analyses for panels of clustered up and downregulated genes. These analyses yield additional pathways and regulators involved in cellular processes such as cell cycle regulation and inflammatory responses. Inappropriate cell cycle regulation could contribute to metabolic deficits, while the immune system has previously been implicated in schizophrenia [90] [91] [92] . Several of our metabolic and immune findings were replicated in other largescale transcriptomic bioinformatic analyses of psychiatric disorders [93] . These results highlight the connectivity of glycolytic pathology in schizophrenia to several systems that could be important targets in future studies.
iLINCS Connectivity Analyses (Drug Discovery)
We divided the top 12 unique perturbagens from our signature connectivity analysis into five groups: PPAR agonists, PI3K inhibitors, antipsychotic drugs, HDAC inhibitors, and other (Table 4 ). PI3K inhibitors constituted two of the drugs that may Breverse^our disease signature. These antitumor drugs inhibit PI3K enzymes, which are part of the PI3K/AKT/ mTOR signaling pathway and play critical roles in many cellular functions such as cellular proliferation, metabolism, and immune cell activation [94] [95] [96] . Recent work has linked schizophrenia pathology to the PI3K-AKT-mTOR signaling cascade [75, 97, 98] . Additionally, PI3K signaling can modulate synaptic formation and plasticity, and is implicated in schizophrenia and autism disorder (reviewed in [97, 99] ). Previous work demonstrated pharmacological inhibition of the catalytic subunit of PI3K blocks amphetamine-induced psychosis in mice, highlighting PI3K inhibitors as therapeutic targets for the treatment of psychiatric disorders [100] . However, PI3K inhibition may be more suitable for Bpositive symptoms,^as PI3K inhibition results in diminished insulinstimulated glucose uptake by inhibiting translocation of GLUT4 glucose transporters to the plasma membrane [101] . Three of our drug discovery analysis hits were typical antipsychotics, which also treat positive symptoms of schizophrenia via dopamine D2 receptor antagonism [102] . It is possible that the glycolytic knockdown signatures used to generate these perturbagens could cause transcriptional changes in L1000 genes involved in the regulation of dopaminergic synapses, suggesting dopamine and metabolic systems could be connected in schizophrenia. This is not entirely surprising as antipsychotics have well-documented metabolic effects [103] .
The top unique perturbagen in our signature connectivity analysis (Table 4) was valproic acid, an HDAC inhibitor that modulates sodium channels and enhances gammaaminobutyric acid (GABA)-mediated neurotransmission (traditionally used to treat epilepsy and bipolar disorder) [104] . Interestingly, sodium valproate (valproic acid) is commonly used as an adjunctive therapy for the treatment of schizophrenia, and a recent 4-week randomized clinical trial demonstrated improvement in psychopathology with a combination therapy of valproate and risperidone or olanzapine compared to antipsychotics alone (n = 249) [105] . There is also some evidence for positive effects on aggression and tardive dyskinesia in schizophrenia, although sample sizes are small [106] . Valproic acid also affects ERK and Wnt pathways, which were implicated in our pathway analyses and regulate cell survival and cytoskeletal modifications [107] . Stimulation of ERK1/2 has the ability to enhance the transcriptional activity of PPARs and increase glucose metabolism, indicating PPAR agonists might also be potential therapeutic targets [108] . Interestingly, two of our unique perturbagen hits included PPAR agonists (troglitazone and Genistein) [109] . Troglitazone, part of the TZD family, is an anti-inflammatory and antidiabetic drug developed to treat type 2 diabetes. Troglitazone is a ligand to both PPARα and (more strongly) PPARγ. It promotes glucose uptake by increasing two transporters we previously found decreased in pyramidal neurons in schizophrenia (GLUT1 and GLUT3), and inhibits the pro-inflammatory factor NFKB (implicated in our Enrichr analyses) [18, 54, 110, 111] . The TZD family of PPAR agonists presents an interesting therapeutic intervention for studies in preclinical models of schizophrenia due to their ability to modulate glucose systems we find abnormal in schizophrenia [112, 113] . Pioglitazone, a current FDA-approved member of the TZD family, also stimulates glycolytic systems and can attenuate mitochondrial dysfunction, reverse memory impairment, and decrease the incidence of dementia [48, 67, [113] [114] [115] [116] [117] [118] . Thus, pioglitazone is an easily accessible drug candidate to Breverse^pathology and possibly restore cognitive defects related to schizophrenia.
To test this hypothesis, we first examined metabolic pathways in the GluN1 knockdown model of schizophrenia. GluN1 knockdown animals display a wide variety of endophenotypes associated with schizophrenia, including deficits in cognition [40] . We found that top pathways associated with protein changes at the synapse in GluN1 knockdown mice compared to WT controls were metabolic in nature (Fig. 5b) . Additionally, expression of glucose transporters (GLUT1 and GLUT3) was significantly decreased in the frontal cortex of GluN1 knockdown mice (Fig. 5c ). These results suggest that there are similar abnormalities in bioenergetic systems in this model and in schizophrenia, and that modulating these systems is a viable treatment strategy. Thus, we examined the effects of pioglitazone, a PPAR agonist that increases glucose uptake, on behavioral endpoints in the GluN1 knockdown model. Pharmacological manipulation of glycolytic pathways via pioglitazone could stimulate glucose uptake and metabolism, possibly restoring some behavioral deficits. We are also able to control for the effects of medication treatments, which can be difficult to interpret in human studies. It is important to distinguish significant metabolic changes as underlying features of the illness and not epiphenomena related to treatment with antipsychotics.
We hypothesized that pioglitazone treatment would improve cognitive function in the GluN1 knockdown model. The puzzle box assay examines cognitive function and becomes progressively more difficult, evident in the similarly poor performance by all groups in later trials. However, in all earlier trials (where GluN1 deficit is more robust), pioglitazone tended to increase WT mean latencies while decreasing GluN1 knockdown mean latencies. Our statistical analyses found that in trial 1 and trial 4, pioglitazone significantly decreased the latency to perform the task in GluN1 knockdown mice (n = 9-12, Fig. 6, panels c and d) . This suggests that in normal physiology, pioglitazone could have a negative effect on learning, while in a pathological brain with impaired synapses, pioglitazone may have restorative effects on cognition.
We also examined the effects of pioglitazone on behaviors reflecting positive and negative schizophrenia symptoms. In line with published findings for this model [39] , our preliminary data suggest that GluN1 knockdown animals have increased locomotor activity and stereotypy compared to WT littermate controls, as well as increased mania and anti-anxiety like behavior (increased % time spent in open arms in EPM compared to WT mice) (Figs. 7 and S19 ). Pioglitazone did not have an effect on these behaviors regardless of genotype, suggesting that either glucose metabolism does not play a role in this phenotype of GluN1 knockdown mice or that this is a neurodevelopmental phenotype that requires earlier intervention.
We did not detect any changes in sociability between any groups. All groups choose to spend more time in the social zone (Fig. S20 ). Previous studies demonstrate inherent social abnormalities in GluN1 knockdown mice, suggesting our experiment may be underpowered to detect an effect on sociability [39] . We also did not detect any changes in social novelty; however, our social novelty data has high variability, which could contribute to lack of significant findings.
Finally, we assessed sensorimotor gating using PPI and acoustic startle response (Fig. 8) . While there were no changes in acoustic startle response across all groups, we detected an effect of genotype on PPI at 4, 8, and 16 dB. GluN1 knockdown mice had generally lower PPI than did WT controls at all decibels. Additionally, at 4 dB, pioglitazone-treated GluN1 knockdown (GluN1pio) mice had a lower PPI than any other group, suggesting pioglitazone interacts in a negative way with the knockdown pathophysiology (drug by genotype interaction). The 4-dB pre-pulse is the lowest level of pre-pulse and thus the Bmost sensitive^measure of the deficit (vs. 8 and 16 dB, where the deficit is sometimes not seen in a disease state). This could explain why we only detect this negative drug interaction at the 4-dB pre-pulse. Interestingly (although not significant), WTpio mice tended to have a larger PPI versus WTveh mice in all decibel tests, while GluN1pio mice tended to have a lower PPI versus GluN1veh mice in all decibel tests, reinforcing the idea of different genotype by drug interactions. PPI as a phenotypic deficit is very predictive for schizophrenia, along with a number of other psychiatric disorders. Although it is used as a measure for efficacy of drugs to treat schizophrenia, it is not always responsive to drugs that work in other phenotypic domains. For example, while atypical antipsychotics are known to ameliorate deficits in PPI, typical antipsychotics have been shown to either have no effect, or even worsen, PPI deficits [119] . Therefore, it is not unusual to see a drug perform in a positive manner in one behavioral domain (for us, puzzle box), while also having no, or negative, effects in another (in our case, PPI). Additional test animals are needed to explore this possibility.
Although the number of animals in each group ranges from n = 6 to 12 and should be considered preliminary, the behavioral phenotypic results described in this study support the previously published findings in the GluN1 knockdown mouse line. It is important to note that amidst the different studies done over the past 20 years, a number of variables may have influenced the severity of the phenotype presented. Most importantly, the age and sex of the mice tested are highly relevant to the severity of phenotype presentation [120] . For this study, we included both sexes, which increases variability; however, the trends in phenotypic presentation remain the same.
Our preliminary findings suggest that pioglitazone may selectively exert its effects on specific endophenotypes of schizophrenia, suggesting circuit-specific modulation of neuroplastic substrates. One possibility is that pioglitazone improves the function of brain regions and circuits that are hypometabolic, while having no effect/negative consequences on brain regions that are normal or hypermetabolic. Many behavioral endpoints that are markers of Bpositive symptomsô f schizophrenia could correspond to Bhypermetabolic^cir-cuitry, and thus not be amenable to rescue via pioglitazone. We found pioglitazone had no effect on behavioral deficits such as hyperactivity, increased stereotypy, and social impairments, which are normalized by typical and atypical antipsychotics in GluN1 knockdown animals [39, 41, [121] [122] [123] [124] . However, pioglitazone did have a restorative effect on cognition (puzzle box assay), while most antipsychotics do not [7, 125] . Interestingly, one study examined the effects of pioglitazone as an adjunct treatment to antipsychotic drugs in schizophrenia subjects (n = 40) [66] . Subjects received risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks.
Patients in the pioglitazone group showed significantly more improvement in Positive and Negative Syndrome Scale (PANSS) negative subscale scores (p < 0.001) as well as PANSS total scores (p = 0.01) compared with the placebo group, suggesting pioglitazone and risperidone work through different circuitry and could be used in conjunction to treat both cognitive/negative and positive symptoms. There is also evidence suggesting pioglitazone treatment could help combat glucose-lipid metabolic abnormalities and diabetes that are often exacerbated by antipsychotics [67] . These findings suggest the possibility of pioglitazone as an augmentation therapy in reducing difficult to treat symptoms in schizophrenia. Studies examining the effects of antipsychotic treatment on cognition in GluN1 knockdown animals have not yet been done and are warranted.
Caveats
Bioinformatics approaches have the potential to offer key insights into our understanding of how specific human diseases or healthy states manifest themselves. However, the techniques presented here have several limitations. Our pathway analyses are inherently biased as the data contained in the contents of Enrichr is limited to previously published experiments. This means that results may be skewed towards systems that are more extensively studied. Additionally, when selecting panels of clustered genes as inputs for Enrichr using dendrograms and clustering (Figs. 3 and 4) , it is not uncommon for 5/6 of the knockdown signatures to change in the same direction for a gene, while 1/6 knockdown signatures have no change or a change in the opposite direction. However, since the goal of the study is to analyze an aggregate signature, we selected clusters of genes that largely change together in the same direction.
Enrichr merges human, mouse, and rat data, an approach that has advantages and disadvantages, such as comprehensive libraries but a lack of species specificity [126] .
For our chemical perturbagen analyses, two seed genes (HK1 and PFKL) had the strongest discordant perturbagen signatures (Table S4) , leading to the overrepresentation of these two seed genes in the overall top 20 chemical perturbagens table (Table S5) . Furthermore, PFKFB2 did not have any discordant signatures to contribute. However, although not in the top 20 overall discordant perturbagen signatures, the top hit for PFKM was also valproic acid (albeit a weak discordance), suggesting our overall top hits may still reverse this signature.
LINCS, although a powerful resource, also has important caveats itself. Knockdown signatures are generated in a variety of cell lines (mostly cancer) and can have differing transcriptomic changes to the same perturbagen. While the selection of a relevant cell line is important, not every target gene has been knocked down in every cell line, and comparing signatures from different cell lines can yield different results. In this study, none of our seed genes had knockdown signatures in neuronal cell lines. To minimize variability, we compared signatures for seed genes using one consistent cell line (VCAP). While these cells are not neuronal cell lines, downstream regulation of transcriptional profiles is often comparable across cell lines, and still provides a useful basis for comparison of mRNA signatures [127] . This is especially true of fundamental aspects of cellular biology, including energy metabolism and related pathways considered here. Interestingly, signatures for troglitazone, an analogue of pioglitazone, are available in the VCAP and neuronal cell lines. Comparison of the L1000 profiles for troglitazone treatment in these cell lines show that they are highly correlated (see online resources). Thus, we can state that although gene knockdown signatures for the genes of interest are not currently available in LINCS neuronal cell lines, the primary drug of interest induces similar signatures in both neuronal and cancer cell lines [128] [129] [130] .
Further, the LINCS database includes 978 Blandmarkĝ enes that are selected as providing representatives of classes of co-expressed genes and to enable imputing the levels of expressions for genes that are not measured directly. There may be instances where this panel does not fully capture the changes found in disease states.
Our in silico Blookup^analyses of metabolic targets in schizophrenia also present challenges. The SMRI database analysis function performs a meta-analysis across 12 independent studies, combining molecularly and functionally distinct brain regions. It is possible that for some genes, regions such as the cerebellum drive results, while more subtle differences in cortical regions are not reported. Additionally, both the SMRI and the MSSM databases were generated for brain regions, and are not cell-subtype specific. It is not surprising that many of our cell-subtype specific findings were not appreciated at the region-level in our Blookup^confirmation studies. Gene expression may be increased in certain cell types and decreased in others, with no net changes [10] . The SMRI database particularly raises concern due to the number of individual studies used for comparison, many of which have varying subject demographics. This notion is supported by the observation that many of our targets are differentially regulated at the cell level in the frontal cortical neuron RNAseq database [76] . Limitations aside, it will be interesting to probe these datasets (and more publicly accessible databases) for targets in pathways that were implicated in our Enrichr analyses (Table 3) .
Our GluN1 knockdown work is not without limitations. While our locomotor and cognitive assay is adequately powered (n = 9-12 per group), EPM, social paradigm, and PPI studies have an average of n = 6 mice per group, which may not be large enough to fully elucidate subtle behavioral differences. It is also possible that pioglitazone doses used here may not fully produce therapeutic effects, and future work with varying dosing regimens is warranted. Additionally, as discussed above, cognition is multifaceted and the current study only utilizes one approach examining executive function (puzzle box assay). Several behavioral tasks such as fear conditioned learning (context versus cue), water maze (contextual memory), radial arm maze (working memory), and novel object recognition task would be useful in determining more nuanced effects of pioglitazone. Finally, additional biochemical experiments in GluN1 knockdown mice could help elucidate other potential metabolic pathways to target. This would provide the framework for future intervention studies using promising new pro-metabolic drugs in GluN1 knockdown mice or pioglitazone in additional models of schizophrenia (i.e., pharmacological models and other mutant models such as DISC1, SHANK3, NRG-1, etc.). This reverse translational approach could also generate targeted questions for future postmortem work.
In summary, we have utilized the LINCS library of genetic and chemical perturbations, coupled with a novel bioinformatics approach to gain insight into the connectivity of bioenergetic pathology in schizophrenia, generated candidate drugs with the potential to reverse the connected pathological signature as opposed to a single target, and restored long-term memory with the PPAR agonist pioglitazone in a preclinical model of schizophrenia. Our work highlights the potential for bioinformatic analyses to identify novel treatment strategies for disorders of cognition and other difficult to treat clinical domains.
Materials and Methods
Human Tissue Acquisition and Preparation DLPFC (Brodmann area 9) postmortem brain samples originated from the Maryland Brain Collection and were distributed by both the Maryland Brain Collection and the Alabama Brain Collection. The cohort consisted of subjects with schizophrenia (n = 16) and nonpsychiatrically ill comparison subjects (n = 16) (Tables S1 and S2 ). Subjects were diagnosed with schizophrenia based on DSM-IV criteria. The medical records of the subjects were examined using a formal blinded medical chart review instrument, as well as in person interviews with the subjects and/or their caregivers, as previously described [131] . Schizophrenia and comparison groups were matched for sex, age, pH, and PMI (Tables S1 and S2 ).
Laser Capture Microdissection
LCM was performed as previously described [11, 18, 59, 60] . Briefly, 14 μm frozen tissue sections containing superficial (II-III) and deep (V-VI) layers of DLPFC were removed from − 80°C storage and allowed to air dry. Tissue sections were rehydrated with distilled H 2 O and then underwent rapid Nissl staining with RNase-treated cresyl violet (1% cresyl violet, 1% glacial acetic acid, pH 4.0). Slides were dehydrated in increasing ethanol concentrations and cleared in Histoclear II (Electron Microscopy Services, USA) for 10 min. After drying in a hood for 15 min, enriched populations of pyramidal neurons or astrocytes (1000 of each cell type per subject) were identified via morphology under the ×20 objective lens and cut using the Applied Biosystems ArcturusXT™ LCM instrument and CapSure Macro LCM caps (Life Technologies, formerly Arcturus, Mountain View, CA, USA) [11, 59, 60] . Laser settings were adjusted prior to each session to produce optimal cutting and capturing with laser settings ranging from 70 to 100 mW in power, and 2000-3000 μs in duration. Separate caps were used for each subject and each cell population. Cells were captured in 4 h sessions as we have previously demonstrated this time frame has minimal effects on messenger RNA (mRNA) integrity [11] . Following cell capture, each cap was incubated with 50 μl of PicoPure RNA extraction buffer (Molecular Devices, Sunnyvale, CA, USA) for 30 min at 42°C. Samples were then centrifuged for 2 min at 800×g and stored at − 80°C until further processing.
RT-qPCR
RNA was treated with RNase-free DNase (79254; Qiagen, NL) during processing. RNA was reverse-transcribed using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). Before PCR experiments, samples were preamplified as previously described [11, 59, 60] .
TaqMan PCR assays for each target gene were performed in duplicate on cDNA samples in MicroAmp Fast Optical 96-well optical plates (Applied Biosystems; Foster City, CA) on an Applied Biosystems detection system (ABI SteponePlus, Applied Biosystems, Life Technologies, USA). For each reaction, 3 μl of cDNA was placed in a 20-μl reaction containing 10 μl of mastermix and 1× dilution of each primer (Applied Biosystems, Life Technologies, USA). Reactions were performed with an initial ramp time of 10 min at 95°C, and 40 subsequent cycles of 15 s at 95°C and 1 min at 60°C. For negative controls for the qPCR reactions, cDNA was omitted (non-template control) or cDNA was generated with reverse transcriptase excluded from the reaction (no RT control). Relative concentrations of the transcripts of interest were calculated with comparison to a standard curve made with dilutions of cDNA from a pooled sampling of all the subjects. Values for the transcripts of interest were normalized to the geometric mean of B2M, β-actin (ACTB), and cyclophilin A (PPIA), housekeeping genes whose expression was unchanged in control and schizophrenia groups (Student's t test, p > 0.05), for the same samples. All TaqMan PCR data were captured using StepOnePlus Software (StepOnePlus Real-Time PCR System; Thermoscientific, Waltham, MA).
Primers
All primers were obtained from Thermo Fisher Scientific, Waltham, MA, USA. Human (Hs); rat (Rn). Targets are as follows: PFKL (Hs00160027_m1), GPI (Hs00976715_m1), B2M (Hs99999907_m1), ACTB (Hs99999903_m1), PPIA (Hs99999904_m1).
Schizophrenia Bioenergetic Profile (Seed Genes)
We began by selecting genes of interest from schizophrenia pathophysiology to build a Bbioenergetic schizophrenia profile.^We selected targets from the glycolytic pathway that were selectively downregulated in this study and our previous studies (GPI, HK1, PFKM, PFKL), as well as dysregulated in the literature (LDHA, PFKFB2) (Table 1) [14, 15, 18] . Knockdown signatures were retrieved for each seed gene in iLINCS, and these knockdown signatures were used in subsequent lookup replication, iLINCS clustering (Enrichr), and iLINCS connectivity (drug discovery) analyses.
In Silico BLookup^Analyses
To replicate our bioenergetic findings in schizophrenia, we probed a publicly available microarray database (SMRI Online Genomics Database), microarray data from the DLPFC of control and schizophrenia subjects (MSSM dataset), and RNAseq data from frontal cortical neurons. The SMRI Online Genomics Database (supported by Dr. Michael Elashoff) was used to assess transcriptomic changes of metabolic targets between 50 schizophrenia and 50 control subjects in multiple brain regions (Brodmann area (BA) 6, BA8/9, BA10, BA46, and the cerebellum) [61] . The MSSM dataset includes microarray data from the DLPFC of schizophrenia (n = 16) and control subjects (n = 15). The RNAseq database contains data from frontal cortical neurons differentiated from iPSCs from a schizophrenia subject with the DISC mutation and an unaffected sibling control subject [76] . Although there is not a clear consensus in the field for what magnitude of fold change is biologically relevant, our ± 1.10 fold change cutoff was picked arbitrarily based on previous preclinical studies showing changes in downstream biological functions in this range [132] [133] [134] [135] . We reported fold change and p values for our metabolic targets in Table 2 .
Generation of Knockdown Signatures for Seed Genes
We used iLINCS (http://ilincs.org) to retrieve knockdown signatures for each seed gene individually. Seed genes often have multiple knockdown signatures from experiments done in different cell lines. We selected the knockdown signature from a VCAP cell line for each seed gene. This was the only cell line with knockdown signatures available for all seed genes. Each seed gene knockdown signature (GPI knockdown signature, HK1 knockdown signature, PFKM knockdown signature, PFKL knockdown signature, LDHA knockdown signature, PFKFB2 knockdown signature) is comprised of the transcriptional changes of 978 landmark genes (L1000 genes) when that seed gene is knocked down. We downloaded the knockdown signatures for each seed gene. Visual representations of the transcriptional changes in L1000 genes for each knockdown signature are presented as heatmaps generated in R Software (R version 3.4.2, 2017 The R Foundation for Statistical Computing) (Fig. S3) . A full list of L1000 genes is available on http://ilincs.org.
iLINCS Clustering Analyses
With the goal of identifying panels of correlated transcriptomic changes in our seed gene knockdown signatures, we used iLINCS to perform unsupervised clustering of the top 50 differentially expressed L1000 genes from our six seed gene knockdown signatures (maximum of 300 L1000 genes) (Figs. 3 and 4) . Due to gene overlap between top 50 differentially expressed L1000 genes in seed gene knockdown signatures, this resulted in the clustering of expression data for 260 L1000 genes. To generate this heatmap, we used the interactive Bgene clusters^function in iLINCS to cluster expression data from 260 differentially expressed genes using Pearson correlation coefficients (Bunion of the top 50 differentially expressed genes^). Using the y-axis dendrogram function, we then selected genes that displayed similar changes in expression across the signatures. We refer to genes that are upregulated across all signatures as Bpanels of clustered upregulated genes^and genes that are downregulated across all signatures as Bpanels of clustered downregulated genes.P anels of clustered upregulated and panels of clustered downregulated gene groups were selected separately and the data was exported to Excel (Table S3 , Figs. 3 and 4) . These clustered gene panels (Table S3) were carried forward to two separate Enrichr analyses.
Enrichr Analyses of Panels of Clustered Upregulated and Downregulated Genes from iLINCS Clustering Analysis
To assess the biological underpinning of correlating transcriptional changes in our seed gene knockdown signatures from iLINCS, we performed traditional pathway analyses on panels of clustered upregulated and panels of clustered downregulated genes using Enrichr (http://amp.pharm.mssm.edu/Enrichr/) ( Table 3 , Figs. S4-S17) [126, 136] . Analyses for panels of clustered upregulated genes (67 genes) and panels of clustered downregulated genes (69 genes) were performed separately. We report results for KEGG cell signaling pathway, GO molecular function, GO cellular components, protein-protein interacting partners, and dbGaP disease implications. Using the ChEA 2016 database in Enrichr, we also report transcription factors that have occupancy sites for a significant number of our panels of clustered genes. Finally, using LINCS L1000 database in Enrichr, we report kinases that when knocked down in specific cell lines, increase or decrease genes that are in our panels of clustered upregulated and downregulated gene data sets, respectively (Table 3, Figs. S4-S17).
With the goal of identifying small drug-like molecules with inverse signatures, we probed iLINCS for chemical perturbagens that result in L1000 transcriptomic signatures that are highly discordant (anti-correlated as denoted by negative concordance values) with each seed gene knockdown signature (potentially reversing the seed gene knockdown signature). This was done individually for each seed gene knockdown signature (unclustered) and the top 20 discordant chemical perturbagen signatures were recorded (Table S4 ). PFKFB2 had no discordant signatures, while GPI and PFKM had less than 20. Perturbagens appearing multiple times for the same seed gene are either in different cell lines or were administered to cells at different concentrations. We also recorded the top 20 overall discordant chemical perturbagen signatures across all seed gene knockdown signatures (Table S5 ). The top 20 overall discordant chemical perturbagen signatures were in the VCAP cell line. When duplicates were removed, 12 unique discordant chemical perturbagen signatures remained (Table 4 ). This list was use to select an FDA-approved drug for preclinical trials.
Experimental Mouse Lines and Genotyping
GluN1 knockdown mice were generated by targeted insertion of the neomycin cassette into intron 19 of Grin1 as previously described [39] . All experimental animals were the F1 progeny of C57Bl/6J and 129X1/SvJ Grin1 heterozygotes. Tail biopsy was used to genotype mice by PCR using the following primers: WT forward 5′-TGA GGG GAA GCT CTT CCT GT-3′, mutant forward 5′-GCT TCC TCG TGC TTT ACG GTAT-3′, common reverse 5′-AAG CGA TTA GAC AAC TAA GGG T-3′. All procedures were approved by the Faculty of Medicine and Pharmacy Animal Care Committee at the University of Toronto, and were conducted in accordance with the Canadian Council in Animal Care (CCAC) guidelines for the care and use of animals. Mice were group housed with littermates on a 12-h light-dark cycle (0700 to 1900 hours) and were given access to food (2018 Teklad Global 18% Protein Rodent Diet, Envigo, Madison Wisconsin USA, www.envigo.com) ad libitum. For biochemical studies, mice were humanely euthanized by rapid cervical dislocation. Whole brains were removed and frozen in dry-ice chilled 2-methylbutane before storage at − 80°C for immunoprecipitation studies.
For our LCMS/IPA and qPCR studies, GluN1 knockdown (n = 5) and WT mice (n = 5) were assayed. For our open field test and puzzle box assay pioglitazone studies, n = 22 WT and n = 21 GluN1 KD mice (Table S6 ). For our EPM, social paradigm, and PPI pioglitazone studies, n = 14 WT and n = 13 GluN1 knockdown mice (Table S6 ).
GluN1 Knockdown LCMS and RT-qPCR Studies
We used a mouse anti-PSD95 antibody (Millipore, catalogue # MAB1596) to capture PSD95 protein complexes from samples (n = 3 male WT, n = 3 male GluN1 knockdown). We verified the specificity of this antibody using multiple reaction monitoring mass spectrometry analysis of PSD95 peptides captured by affinity purification. Five micrograms of PSD95 antibody was coupled per 1 mg of Dynabeads (Life Technologies) according to the antibody coupling kit protocol (#14311D). For each sample, 1000 μl of 10 mg/ml antibody coupled beads was washed 2× 1 ml with ice cold 1× PBST (#9809S, Cell Signaling) then incubated with mouse brain lysate brought to a final volume of 1000 μl with ice cold 1× PBST for 1 h at room temperature. The supernatant was removed and the beads were washed 4 × 10 min at room temperature in 1 ml ice cold 1× PBST. Captured protein complexes were eluted with 30 μl of 1 N Ammonium Hydroxide (#320145, Sigma), 5 mM EDTA, pH 12 for 10 min at room temperature. Six microliters of 6× protein denaturing buffer (4.5% SDS, 15% β-mercaptoethanol, 0.018% bromophenol blue, and 36% glycerol in 170 mM Tris-HCl, pH 6.8) was added to each sample elution. The eluted samples were heated at 70°C for 10 min then processed for mass spectrometry.
All samples (n = 3 male WT, n = 3 male GluN1 knockdown) were loaded on a 1.5 mm, 4-12% Bis-Tris Invitrogen NuPage gel (NP0335BOX) and electrophoresed in 1× MES buffer (NP0002) for 10 min at 180 V. The gel was fixed in 50% ethanol/10% acetic acid overnight at RT, then washed in 30% ethanol for 10 min followed by two 10 min washes in MilliQ water (MilliQ Gradient system). The lanes were harvested, cut into small (~2 mm) squares, and subjected to ingel tryptic digestion and peptide recovery. Representative western blots are seen in Fig. 5a . Samples were resuspended in 0.1% formic acid.
Nano liquid chromatography coupled electrospray tandem mass spectrometry (nLC-ESI-MS/MS) analyses were performed on a 5600+ QTOF mass spectrometer (Sciex, Toronto, On, Canada) interfaced to an Eksigent (Dublin, CA) nanoLC.ultra nanoflow system. Peptides were loaded (via an Eksigent nanoLC.as-2 autosampler) onto an IntegraFrit Trap Column (outer diameter of 360 μm, inner diameter of 100 μm, and 25 μm packed bed) from New Objective, Inc. (Woburn, MA) at 2 μl/min in formic acid/H 2 O 0.1/99.9 (v/v) for 15 min to desalt and concentrate the samples. For the chromatographic separation of peptides, the trap column was switched to align with the analytical column, Acclaim PepMap100 (inner diameter of 75 μm, length of 15 cm, C18 particle sizes of 3 μm, and pore sizes of 100 Å) from DionexThermo Fisher Scientific (Sunnyvale, CA). The peptides were eluted using a variable mobile phase (MP) gradient from 95% phase A (formic acid/H 2 O 0.1/99.9, v/v) to 40% phase B (formic acid/acetonitrile 0.1/99.9, v/v) for 70 min, from 40% phase B to 85% phase B for 5 min and then keeping the same mobile phase composition for five additional minutes at 300 nl/ min. The nLC effluent was ionized and sprayed into the mass spectrometer using NANOSpray® III Source (Sciex). Ion source gas 1 (GS1), ion source gas 2 (GS2), and curtain gas (CUR) were respectively kept at 8, 0, and 35 vendor specified arbitrary units. The mass spectrometer method was operated in positive ion mode and the interface heater temperature and ion spray voltage were kept at 150°C and at 2.6 kV, respectively. The data was recorded using Analyst-TF (version 1.7) software.
The data independent acquisition (DIA) method was set to go through 1757 cycles for 99 min, where each cycle performed one TOF-MS scan type (0.25 s accumulation time, in a 550.0 to 830.0 m/z window) followed by 56 sequential overlapping windows of 6 Da each. Note that the Analyst software automatically adds 1 Da to each window to provide overlap; thus, an input of 5 Da in the method set up window results in an overlapping 6 Da collection window width (e.g., 550-556, then 555-561, 560-566, etc). Within each window, a charge state of + 2, high sensitivity mode, and rolling collision energy with a collision energy spread (CES) of 15 V were selected.
Protalizer DIA software (Vulcan Analytical, Birmingham, AL) was used to analyze every DIA file (Sciex 5600 QTOFs). The Swiss-Prot Homo sapien database, downloaded March 17th 2015, was used as the reference database for all MS/MS searches. A precursor and fragment-ion tolerance for QTOF instrumentation was used for the Protalizer Caterpillar spectral-library free identification algorithm. Potential modifications included in the searches were phosphorylation at S, T, and Y residues, N-terminal acetylation, N-terminal loss of ammonia at C residues, and pyroglutamic acid at N-terminal E and Q residues. Carbamidomethylation of C residues was searched as a fixed modification. The maximum valid protein and peptide expectation score from the X! Tandem search engine used for peptide and protein identification on reconstructed spectra was set to 0.005.
For DIA quantification by Protalizer, the maximum number of b and y series fragment-ion transitions was set to nine excluding those with m/z values below 300 and not containing at least 10% of the relative intensity of the strongest fragmention assigned to a peptide. A minimum of five fragment-ions were required for a peptide to be quantified (except where indicated otherwise). In datasets where a minimum of seven consistent fragment-ions were not detected for the same peptide ion in each of the three files compared in a triplicate analysis, the algorithm identified the file with the largest sum fragment-ion AUC and extracted up to seven of these in the other files using normalized retention time coordinates based on peptides detected by the Caterpillar algorithm in all the files in a dataset.
To generate the top pathways for GluN1 knockdown mice, we input the top 20 increased proteins in GluN1 knockdown mice relative to WT mice from LCMS experiments into IPA. The top 5 implicated pathways are reported in Fig. 5b .
Finally, we examined the mRNA expression of metabolic transporters using real-time quantitative polymerase chain reaction (RT-qPCR in a cohort of GluN1 knockdown and WT mice (n = 5 per group) (Fig. 5c) . TaqMan PCR assays for each target gene were performed in duplicate on cDNA samples in 96-well optical plates using StepOnePlus machine (StepOnePlus Real-Time PCR System; Thermoscientific, Waltham, MA). All TaqMan PCR data were captured using Sequence Detector Software (SDS version 1.6; PE Applied Biosystems). All primers were obtained from Thermo Fisher Scientific, Waltham, MA, USA. Targets are as follows: MCT1 (Mm01306379_m1), MCT2 (Mm00441442_m1), MCT4 (Mm00446102_m1), GLUT1 (Mm00441480_m1), and GLUT3 (Mm00441483_m1).
Drug Administration for GluN1 Knockdown Pioglitazone Studies
Pioglitazone is an FDA-approved drug for the treatment of type II diabetes. It increases the transport of glucose from the bloodstream into tissues by increasing the expression of the glucose transporter GLUT1. We divided mice into four groups: for the open field test and puzzle box assay, WTveh (n = 12), WTpio (n = 10), GluN1veh (n = 9), and GluN1pio (n = 12), and for EPM, social paradigm, and PPI tasks, WTveh (n = 6), WTpio (n = 8), GluN1veh (n = 4), and GluN1pio (n = 9). On day 1 of the experimental paradigm, mice were given free access to either a 2018 Teklad Global 18% Protein Rodent Diet (Envigo, Madison, WI, USA, www.envigo.com) as control (Bvehicle^) chow or chow infused with pioglitazone at 100 ppm (2018 Teklad with 0.01% pio, BOCSCI, Shirley, NY, USA) for 7 days. Dose was selected based on previous studies [54] . On day 8, behavioral tests began (animals remained on respective diets until sacrificed on day 17). Throughout the experiments, we assessed caloric intake and body weight to monitor pioglitazone's effects on health (Fig.  S18 ).
Behavioral Testing
F1 male and female Grin1fl neo/Cre mice were used for all behavioral testing, along with WT littermates as controls. Animals were aged 10-12 weeks. All behavioral tests were completed between 0900 and 1500 hours. Animals were weighed at the beginning of the experiment and on days 7 and 14. Food was also weighed throughout experiments (Fig. S18) . On day 7, all mice had their locomotor activity and stereotypy behavior measured in the open field test. On day 9, mice were tested on the EPM. Days 10 through 12, mice were tested in the puzzle box assay. Day 15 mice were subjected to the social affiliative paradigm, and finally on day 16, PPI was tested. A timetable is presented in Table S7 .
Open Field Test
Locomotor activity and stereotypy were measured using digital activity monitors (Omnitech Electronics, Columbus, OH, USA) on the first day of behavioral testing (day 8 of overall experimental paradigm) as previously described [120] . Naïve mice were placed in novel Plexiglas arenas (20 × 20 × 45 cm) and their locomotor and stereotypic activity was recorded over a 120-min period in dim light (15-16 lx) . Activity was tracked via infrared light beam sensors; total distance traveled and stereotypic movements were collected in 5-min bins.
Elevated Plus Maze
Anxiety behavior was assessed on day 9 of testing via the EPM [137] 
Puzzle Box Assay
Mice were run on the puzzle box assay on days 10-12 of testing to assess cognition and executive function as previously described [120] . Consisting of two compartments, the puzzle box contains a start area (58 × 28 × 27.5 cm) in bright light (250 lx) and a goal zone (14 × 28 × 27.5 cm) in dim light (5 lx). Briefly, mice are placed in the brightly lit compartment and quickly develop preference for a smaller dark goal compartment due to light/dark motivation [56] . The two areas are separated by a black Plexiglas divider, but connected via an underpass large enough for mice to pass through easily. Mice were placed in the start box facing away from the divider, and the time to move to the goal zone (through the underpass, with both hind legs in the goal zone) was manually scored and recorded. Mice were tested over 3 days, three trials/day, with each day consisting of increasingly difficult obstacles present in the underpass connecting the start area and the goal zone. Two minutes was given between each trial on a given day, with a max 300 s allowed for the completion of each trial. The trials (and obstacles) for the puzzle box were as follows:
Day 10: T1 (training) open door and unblocked underpass, T2 and T3 (challenge, then learning) doorway closed and underpass open Day 11: T4 (long-term memory) identical to T3, T5, and T6 (challenge, then learning) underpass filled with bedding (similar to that found in home cage) Day 12: T7 (long-term memory) identical to T6, T8, and T9 (challenge, then learning) underpass blocked by a removable cardboard plug
Social Affiliative Paradigm
Social affiliative behavior was assessed on day 15 of testing, as previously described [120, 138] . Sociability was measured via video recording the motion and exploration of the experimental mouse, tracked via Biobserve Viewer (version 2) software (center body-reference point). Experimental mice were allowed to explore the open area (opaque white walls, 62 × 42 × 22 cm) for 10 min in dim lighting (15-16 lx) . The area contained two inverted wire cups, one containing a stimulus mouse (Bsocial^) and the other empty (Bnon-social^). Time spent in each zone (3 cm zone around the cup) was recorded via the Biobserve software. Mice used as a social stimulus were novel, WT, inbred C57Bl/6 mice that were age-and sex-matched to the test mouse.
Pre-pulse Inhibition/Acoustic Startle Reflex PPI of the acoustic startle response was measured on day 16, via SR-LAB equipment and software from San Diego Instruments (San Diego Instruments, San Diego, CA, USA). Accelerometers were calibrated to 700 ± 5 mV and output voltages were amplified and analyzed for voltage changes using SR Analysis, and exported as an Excel file. Background white noise was maintained at 65 dB. PPI was measured in a 30-min test with 80 randomized trials of (1) 10 trials pulse alone, (2) 10 trials pre-pulse alone (for each pre-pulse), (3) 10 trials pre-pulse plus pulse (for each pre-pulse), and (4) 10 trials no pulse. Five pulse alone trials were performed before and after the 80 trials, totaling 90 trials per run. The pre-pulse (4, 8, or 16 dB) was presented 100 ms prior to the startle pulse (165 dB). The inter-stimulus interval (ISI) was randomized between 5 and 20 s. Experimental mice were placed in a cylindrical tube on a platform in a soundproof chamber. Mice were allowed to acclimatize in the chamber and to the background noise for 300 s, followed by 5 consecutive pulse alone trials, then by 80 randomized trials (as described above) and then 5 consecutive pulse alone trials. PPI was measured as a decrease in the amplitude of startle response to a 100-dB acoustic startle pulse, following each pre-pulse (4, 8, and 16 dB).
Statistical Analysis
Statistical analyses for human LCM-qPCR were as follows: data were analyzed using Statistica 13.0 (Statsoft, Tulsa, OK, USA) and GraphPad Prism (La Jolla, CA, USA). Outliers were removed from data sets using the ROUT method (Q = 5%). All dependent measures were tested for normalcy and homogeneity of variance using D'Agostino & Pearson omnibus normality test followed by Student's t tests. We probed for associations between our dependent measures and pH, PMI, age, and RIN using correlation analyses. We did not detect any significant correlations between age, pH, RIN, and PMI with any of our dependent measures.
In addition to PMI, pH, and age, we performed secondary analyses (using t tests) to examine ethanol use, smoking, and laterality as grouping variables in our schizophrenia subjects and found no significant effects. We also performed t tests after removing antipsychotic naïve subjects and all targets remained significant. No subjects had any dependence for cocaine, sedatives, cannabis, amphetamines, hallucinogens, inhalants, or opioid dependence (only subject 828 took morphine for pain). Subjects with prolonged agonal states were not included in this cohort.
Statistical analyses for animal behavioral assays were as follows: All dependent measures were tested for normalcy and homogeneity of variance using D'Agostino & Pearson omnibus normality test. For locomotor activity, stereotypy, vertical activity, EPM, social and social novelty, and PPI/ acoustic startle response, we performed two-way ANOVA with Bonferroni multiple comparison corrections. Each decibel in PPI was treated as an individual ANOVA (4, 8, 16 dB) .
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